Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...

Research and development (R&D) expenses were $1.0 million for the quarter ended June 30, 2025 compared to $0.8 million for the quarter ended June 30, 2024. The $0.2 million increase was primarily due ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial ...

Received FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune ...

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, ...

Douglas was diagnosed with IV squamous cell carcinoma oral cancer, fearing he would have to have part of his jaw removed. The side effects of his treatment were horrific, with burns to his palate. He ...

IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients. Click ...

Knocking down EPIC1 sensitized triple negative breast tumor-bearing mice to immunotherapy with the PD-1 inhibitor pembrolizumab.